Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Erectile dysfunction (ED) is a common form of organic sexual dysfunction in males with
diabetes, with estimated incidence rates between 35 and 75%. Fifty percent of men with
diabetes are afflicted with ED within 10 years of their diagnosis. Long-term poor glycemic
control increases the risk ED. Although comparatively costly, advantages of CSII over other
modes of insulin delivery include better glycemic control, fewer hypoglycemic episodes, and
improved quality of life. In a previously published study, on CSII in T2DM, in our center,
83% of men reported an improvement in sexual function as a secondary endpoint. The current
study is planned to further explore this finding.